相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
Maxime Cochin et al.
ANTIVIRAL RESEARCH (2022)
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
Jean-Francois Rossignol et al.
ECLINICALMEDICINE (2022)
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajith K. R. Rajoli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19
Amit S. Lokhande et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
Patricia R. M. Rocco et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew Stachulski et al.
ACS INFECTIOUS DISEASES (2021)
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
Luca Braga et al.
NATURE (2021)
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Jean-Selim Driouich et al.
NATURE COMMUNICATIONS (2021)
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
Franck Touret et al.
ANTIVIRAL RESEARCH (2021)
Nitazoxanide superiority to placebo to treat moderate COVID-19-A Pilot prove of concept randomized double-blind clinical trial
Vinicius Fontanesi Blum et al.
ECLINICALMEDICINE (2021)
Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis
K. F. Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Usman Arshad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Repurposing old drugs as antiviral agents for coronaviruses
Cheng-Wei Yang et al.
BIOMEDICAL JOURNAL (2020)
Potential role for nitazoxanide in treating SARS-CoV-2 infection
Paulo Ricardo Martins-Filho et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2020)
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
Daniel F. Alonso et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Natural history of COVID-19 and current knowledge on treatment therapeutic options
Wagner Gouvea dos Santos
BIOMEDICINE & PHARMACOTHERAPY (2020)
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Nina Le Bert et al.
NATURE (2020)
Advances in the possible treatment of COVID-19: A review
Pankaj Chibber et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret et al.
SCIENTIFIC REPORTS (2020)
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
Ahmed Mostafa et al.
PHARMACEUTICALS (2020)
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Dina B. Mahmoud et al.
JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY (2020)
Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery
Franck Touret et al.
ANTIVIRAL RESEARCH (2019)
Advances in respiratory virus therapeutics - A meeting report from the 6th for isirv Antiviral Group conference
John H. Beigel et al.
ANTIVIRAL RESEARCH (2019)
Pharmacokinetics, Metabolism, and Partial Biodistribution of Pincer Therapeutic Nitazoxanide in Mice following Pulmonary Delivery of lnhalable Particles
Anuradha Gupta et al.
MOLECULAR PHARMACEUTICS (2017)
Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture
Elizabeth P. Harausz et al.
TUBERCULOSIS (2016)
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Jean-Francois Rossingol
JOURNAL OF INFECTION AND PUBLIC HEALTH (2016)
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
Jianzhong Cao et al.
ANTIVIRAL RESEARCH (2015)
Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro
Giuseppe Belardo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Antiviral Activity of Substituted Salicylanilides - A Review
M. Kratky et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2011)
The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2α Via Protein Kinase Activated by Double-Stranded RNA Activation
Menashe Elazar et al.
GASTROENTEROLOGY (2009)
Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level
Jean Francois Rossignol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
分享论文
